Lycored will be developing a new formulation combining its Lycomato lycopene with omega-3 fatty acids.
Photo © iStockphoto.com/fotokostic
Lycored (Secaucus, NJ) has announced that it has been granted a U.S. patent for a composition comprising omega-3 fatty acid with patented tomato extract lycopene, Lycomato, and optionally with carnosic acid and or/lutein. The combination has been found to work synergistically to support healthy inflammation in the body, inhibiting inflammatory markers by suppressing anti-inflammatory mediators, says the company. Lycored recently published a study in NeuroMolecular Medicine demonstrating the combination’s ability to balance inflammatory markers in the brain.
“Lycored is currently in the process of developing a new formulation that directly addresses the components of this new patent, which would enhance the use of existing omega-3 products, and benefits to inflammatory markers that support overall brain health,” said Karin Hermoni, PhD, head of science and nutrition at Lycored, in a press release. “This patent is a milestone in Lycored’s plan program for developing innovative solutions for brain health, and we are excited to implement this new patent into our already extensive portfolio.”
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
May 14th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.